Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q2 FY23 results · Jul–Sep 2022
Supriya Lifescience reported revenue from operations of ₹112.17 crore and net profit of ₹16.86 crore for Q2 FY23 (Jul–Sep 2022), on a standalone basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 112.17 | — | — | 101.36 | +10.7% |
| Other income | 2.60 | — | — | 2.36 | +10.5% |
| Total income | 114.78 | — | — | 103.71 | +10.7% |
| Profit before tax | 27.42 | — | — | 30.14 | −9.0% |
| Net profit for the period | 16.86 | — | — | 25.25 | −33.2% |
| EPS, basic (₹) | 2.10 | — | — | 3.14 | −33.1% |
| Net margin (%) | 15.0 | — | 24.9 |
Standalone
- Filed with BSE
- 23 Nov 2022, 15:47 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE